TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos†or the "Company†), a clinical-stage biotechnology company developing life- improving medicines to treat degenerative muscle diseases, today announced new data further demonstrating tolerability and initial efficacy of SAT-3247 in adults (aged 20-27 years) with Duchenne muscular dystrophy (Duchenne or DMD) at the 30 Annual Congress of the World Muscle Society in Vienna, Austria. "Satellos' new and updated clinical resul ...